Divi's Laboratories Ltd.

NSE: DIVISLAB | BSE: 532488 | ISIN: INE361B01024 | Industry: Pharmaceuticals
| Expensive Star
6025.5000 65.00 (1.09%)
NSE May 09, 2025 15:31 PM
Volume: 450.0K
 

6025.50
1.09%
BOB Capital Markets Ltd.
FY20 to be a slow growth year downgrade to REDUCE Q4FY19 was a big miss after a solid beat in the last two quarters. Revenue/EBITDA were 8%/23% below estimates. A large part of the miss was due to increase in RM prices, which would take 5-6 months to normalise, and a weak product mix. FY20 should be a year of slower growth (after a high base in FY19), with management guiding for 10% revenue growth and steady margins. This along with full valuations drives our rating cut to REDUCE (vs. ADD) with...
Divi's Laboratories Ltd. is trading above all available SMAs
More from Divi's Laboratories Ltd.
Recommended